Destiny Pharma has appointed MedPharm to develop new formulations of its XF-platform compounds as treatments for dermal and ocular infections. MedPharm will develop compounds for the treatment of several topically treated infections, including diabetic foot ulcers and ophthalmic infections. The XF-platform has already delivered XF-73 nasal gel for the prevention of post-surgical infections. The phase 2b testing trial will begin in 2019.
Neil Clark, Destiny Pharma’s CEO, commented: “We are pleased to be working with MedPharm and using their globally recognised expertise to develop effective, patient-friendly formulations of XF and DPD drugs from our novel antimicrobial XF-platform. There is an unmet medical need for novel anti-infectives that address dermal and ocular infections with a significantly reduced level of antimicrobial resistance.”